Abstract | INTRODUCTION: In the last couple of years, the number of patients with chronic inflammatory rheumatic diseases being treated with TNF α antagonist has increased dramatically. Adalimumab, a fully human monoclonal antibody against TNF α, is one of the most frequently administered TNF α antagonists. Yet, unresolved issues are the long-term safety of TNF α antagonists and high treatment costs. AREAS COVERED: EXPERT OPINION:
|
Authors | Denis Poddubnyy, Martin Rudwaleit |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 10
Issue 4
Pg. 655-73
(Jul 2011)
ISSN: 1744-764X [Electronic] England |
PMID | 21554150
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Tumor Necrosis Factor-alpha
- Adalimumab
|
Topics |
- Adalimumab
- Animals
- Antibodies, Monoclonal, Humanized
(adverse effects, metabolism, therapeutic use)
- Arthritis, Psoriatic
(diagnostic imaging, drug therapy, metabolism)
- Arthritis, Rheumatoid
(diagnostic imaging, drug therapy, metabolism)
- Clinical Trials as Topic
(methods)
- Drug-Related Side Effects and Adverse Reactions
(chemically induced, metabolism)
- Humans
- Radiography
- Spondylitis, Ankylosing
(diagnostic imaging, drug therapy, metabolism)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, metabolism)
|